TFA-01 Dose-Finding Study Scheduled to Begin October 21, Followed by a Four-Arm Canine Osteoarthritis Trial

TFA Therapeutics, Inc. has completed delivery of the TFA-01 injectable nanoformulation and coordination with the clinical trial site. Shanghai Pet-Sci is scheduled to begin a dose-finding study on October 21, 2026. This stage aims to identify an effective dose and dosing regimen, after which a four-arm canine osteoarthritis trial will follow to advance TFA-01 clinical development.

The dose-finding results will inform dosing in the subsequent controlled trial. The follow-on study will involve dogs with osteoarthritis and is planned to use placebo and active comparators across four arms:

The four-arm study will evaluate TFA-01 efficacy relative to placebo and compare its efficacy and safety with a corticosteroid and a nonsteroidal anti-inflammatory drug. The resulting comparisons with existing treatments will provide data to inform further clinical development and preparation of a regulatory submission.

The injectable nanoformulation used in this study was developed by the Taiwan Animal Vaccine Research Institute and collaborating research teams. TFA Chief Technology Officer Vincent Liu visited Shanghai Pet-Sci to review the trial environment and animal-care arrangements, and to confirm trial procedures and plans for subsequent execution with the clinical team.

Subsequent clinical work will proceed in accordance with applicable Chinese new veterinary drug registration requirements and the Good Clinical Practice for Veterinary Drugs (veterinary GCP), covering dosing, observations and assessments, source-data recording and trial reporting. The program will continue to generate canine osteoarthritis efficacy and safety data to support preparations for a TFA-01 regulatory submission.